Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses unresolved treatment choices in chronic lymphocytic leukemia.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD
Advertisement
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, is a consultant hematologist and associate professor at Peter MacCallum Cancer Centre in Australia.
Articles by Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
4
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
5